Abstract |
Patients with myelodysplastic syndromes (MDS) who resist or fail to respond to hypomethylating agents (HMAs) show very poor outcomes and have no effective treatment strategies. Therefore, new therapeutic approaches are urgently needed for MDS patients harboring adverse prognostic factors. Repurposing disulfiram (DSF), an alcohol-abuse drug, with or without Copper (Cu) has attracted considerable attentions as a candidate anti- tumor therapy in diverse malignancies. However, the effect of DSF in the presence or absence of Cu on MDS has not been reported yet. In this study, we found that monotherapy with DSF showed mild cytotoxic effects on MDS preclinical models. However, the anti- tumor activity of DSF was significantly enhanced in the presence of Cu in MDS in vitro and in vivo with minimal safety profiles. DSF/Cu combination blocked MDS cell cycle progression at the G0/G1 phase, accompanied by reduction of the S phase. Accordingly, co-treatment with DSF and Cu downregulated the expression of Cyclin D1 and Cyclin A2, whereas this combination upregulated the level of P21 and P27. Mechanistically, the anti-MDS effectiveness of DSF/Cu was potentially associated with activation of the ER stress-related Bip pathway and inactivation of the Akt pathway. In addition, inhibition of autophagy process also contributed to the cytotoxicity of DSF/Cu in MDS cells. In conclusion, these findings provide impressive evidence that the DSF/Cu complex shows potent anti- tumor efficacies on MDS preclinical models, representing a potential alternative therapy for MDS patients and warranting further investigation in clinical contexts.
|
Authors | Jie Zha, Silei Bi, Manman Deng, Kai Chen, Pengcheng Shi, Liying Feng, Jixiang He, Xuan Pu, Chengcen Guo, Haijun Zhao, Zhifeng Li, Yirong Jiang, Haihan Song, Bing Xu |
Journal | European journal of pharmacology
(Eur J Pharmacol)
Vol. 902
Pg. 174107
(Jul 05 2021)
ISSN: 1879-0712 [Electronic] Netherlands |
PMID | 33865831
(Publication Type: Journal Article)
|
Copyright | Copyright © 2021 Elsevier B.V. All rights reserved. |
Chemical References |
- Antineoplastic Agents
- Endoplasmic Reticulum Chaperone BiP
- Heat-Shock Proteins
- Copper
- Proto-Oncogene Proteins c-akt
- Disulfiram
|
Topics |
- Animals
- Antineoplastic Agents
(pharmacology, therapeutic use)
- Apoptosis
(drug effects)
- Autophagy
(drug effects)
- Cell Cycle
(drug effects)
- Cell Line, Tumor
- Cell Proliferation
(drug effects)
- Copper
(pharmacology, therapeutic use)
- Disulfiram
(pharmacology, therapeutic use)
- Endoplasmic Reticulum Chaperone BiP
- Endoplasmic Reticulum Stress
(drug effects)
- Female
- Heat-Shock Proteins
(metabolism)
- Humans
- Mice, Inbred BALB C
- Mice, Inbred C57BL
- Mice, Nude
- Mitochondria
(drug effects)
- Myelodysplastic Syndromes
(drug therapy, pathology)
- Proto-Oncogene Proteins c-akt
(metabolism)
- Xenograft Model Antitumor Assays
- Mice
|